CA19-9（癌抗原19-9）腫瘤標(biāo)志物相關(guān)抗體
- 中文名稱：CA19-9（癌抗原19-9）腫瘤標(biāo)志物相關(guān)抗體
二、產(chǎn)品描述
CA19-9是胰腺癌和結(jié)、直腸癌的標(biāo)志物，血清癌抗原19-9可作為胰腺癌，膽囊癌等惡性腫瘤的輔助診斷指標(biāo)。胚胎期胎兒的胰腺、膽囊、肝、腸等組織存在這種抗原，正常人體組織中含量很低；在消化道惡性腫瘤，尤其是胰腺癌、膽囊癌病人血清中，癌抗原19-9含量明顯增高，但早期診斷價值不大，主要作為病情監(jiān)測和預(yù)示復(fù)發(fā)的指標(biāo)。此外，對消化道疾病鑒別診斷（如胰腺癌與胰腺炎。胃癌與胃潰瘍）亦有一定價值。
三、相關(guān)產(chǎn)品
Anti-Human CA19-9/CA199 Monoclonal Antibody (1A297) (MHK33901)
Anti-Human CA19-9/CA199 Monoclonal Antibody (1A298) (MHK33902)
Anti-Human CA19-9/CA199 Monoclonal Antibody (1A299) (MHK33903)
Anti-Human CA19-9/CA199 Monoclonal Antibody (1A300) (MHK33904)
Anti-sLea/CA19-9 Antibody (1116NS19.9) (FHK33910)
Anti-sLea/CA19-9 Antibody (7E3#) (FHK33920)
InVivoMAb Anti-sLea/CA19-9 Antibody (Iv0123) (VHK33901)
Anti-sLea/CA19-9 Antibody (SAA0808) (RHK33901)
Research Grade Anti-Human CA19-9/Sialyl Lewis A (sLe A) Antibody (MVT-5873) (DHK33901)
四、產(chǎn)品詳情
名稱：Anti-Human CA19-9/CA199 Monoclonal Antibody (1A297) (MHK33901)
別名：CA19-9（癌抗原19-9）腫瘤標(biāo)志物，CA199，Carbohydrate antigen199, Carbohydrate antigen 19-9，癌抗原19-9，Anti CA19-9
貨號：MHK33901
種屬反應(yīng)性：Human
宿主：Mouse
同種型：IgG
克隆類型：Monoclonal
免疫原：Human CA19-9/CA199 Protein.
靶標(biāo)：CA19-9, CA199, Carbohydrate antigen199, Carbohydrate antigen 19-9
濃度：1 mg/ml
內(nèi)毒素水平：Please contact with the lab for this information.
純度：>95% as determined by SDS-PAGE.
純化方式：Protein A/G purified from cell culture supernatant.
克隆號：1A297
應(yīng)用：ELISA
狀態(tài)：Liquid
保存溶液：0.01M PBS, pH 7.4.
穩(wěn)定性和存儲：Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term. (MHK33901)
五、參考文獻(xiàn)：
CA 19-9: Biochemical and Clinical Aspects. PMID: 26530370
Comparing the diagnostic accuracy of five common tumour biomarkers and CA19-9 for pancreatic cancer: a protocol for a network meta-analysis of diagnostic test accuracy. PMID: 29282264
CA19-9 and CEA biosensors in pancreatic cancer. PMID: 38246211
CA19-9. PMID: 10778164
Monitoring Ca19-9 during pancreatic cyst surveillance: Better safe than sorry? PMID: 37573577
CA19-9: more than just a biomarker?. PMID: 31931544
CA19-9: the Italian experience. PMID: 7846014
Preoperative CA19-9 and GGT ratio as a prognostic indicator in ampullary carcinoma. PMID: 36915042
Diagnostic Accuracy of Serum CA19-9 in Patients with Cholangiocarcinoma: A Systematic Review and Meta-Analysis. PMID: 26576628
Elevated CA19-9 levels; not always cancer. PMID: 33651490
The clinical significance of elevated levels of serum CA 19-9. PMID: 15190651
CA19-9 With Two-stage Resection Is Useful for Conversion Surgery in PDAC With Synchronous Oligometastases. PMID: 37909951
Extremely high serum CA19-9 level along with elevated D-dimer in assisting detection of ruptured ovarian endometriosis. PMID: 35733415
Ratio of CA19-9 Level to Total Tumor Volume as a Prognostic Predictor of Pancreatic Carcinoma After Curative Resection. PMID: 35138217
CA19.9 decrease >15% is a predictor of favourable outcome in patients treated for advanced pancreatic carcinoma: analysis of two independent cohorts. PMID: 30466797
Optimize CA19-9 in detecting pancreatic cancer by Lewis and Secretor genotyping. PMID: 27692554
CA19-9 kinetics during systemic chemotherapy in patients with advanced or recurrent biliary tract cancer. PMID: 29038848
Electrochemical Immunoassay for Tumor Marker CA19-9 Detection Based on Self-Assembled Monolayer. PMID: 35889454
Glycoprotein CA19.9-specific monoclonal antibodies recognize sialic acid-independent glycotope. PMID: 29072130
Platelet-to-lymphocyte ratio and CA19-9 are simple and informative prognostic factors in patients with resected pancreatic cancer. PMID: 31000337
CA19-9-producing transitional cell carcinoma of the renal pelvis: a case report. PMID: 11329962
High level of tumor marker CA19-9 returned to normal after cholecystectomy in calculous cholecystitis patients. PMID: 36644950
Prognostic Relevance of PDL1 and CA19-9 Expression in Gallbladder Cancer vs. Inflammatory Lesions. PMID: 36826082
High Serum CA19-9 Concentration Indicates High Chemosensitivity and Better Survival in Advanced Urothelial Carcinoma. PMID: 30591483
CA19-9 has no value as a tumor marker in obstructive jaundice. PMID: 10065510
CA19-9 is a significant prognostic factor in stage III gastric cancer patients undergoing radical gastrectomy. PMID: 38263014
Biomolecular Recognition of the Glycan Neoantigen CA19-9 by Distinct Antibodies. PMID: 34119488
Predictive Value of Preoperative Serum CA19-9 on Margin Status. PMID: 31638508
The prognostic value of CA19-9 response after neoadjuvant therapy in patients with pancreatic cancer: a systematic review and pooled analysis. PMID: 33047181
Combination of preoperative CA19-9 levels, cell differentiation, and age predicts survival for patients with gastric cancer before surgery. PMID: 34889247
Bronchioloalveolar carcinoma producing CA19-9. PMID: 21682047
A Rare Cause of Elevated Serum CA19-9. PMID: 32828817
Serum carbohydrate antigen 19-9 in pancreatic adenocarcinoma: a mini review for surgeons. PMID: 28803454
CA19-9 in intrahepatic cholangiocarcinoma : A diagnostic and prognostic armamentarium?. PMID: 29644426
SERS-based immunoassay and degradation of CA19-9 mediated by gold nanowires anchored magnetic-semiconductor nanocomposites. PMID: 33265038
Comment re: "Optimize CA19-9 in detecting pancreatic cancer by Lewis and Secretor genotyping". PMID: 28434838
Serum CA19-9 is a significant predictor among preoperative parameters for early recurrence after resection of pancreatic adenocarcinoma. PMID: 22411488
A Case of Pseudoelevation of Serum CA19-9 Level. PMID: 38213206
The implication of tumor biomarker CA19-9 in the diagnosis of intracranial epidermoid cyst. PMID: 27793056
Anti-CA19-9 diabody as a PET imaging probe for pancreas cancer. PMID: 21601881
詳情請咨詢Antibodysystem中國授權(quán)總代理-武漢佰樂博生物技術(shù)有限公司
網(wǎng)址：https://www.antibodysystem.com/product/20998.html
武漢佰樂博生物技術(shù)有限公司作為法國Antibodysystem品牌亞洲區(qū)授權(quán)總代理。提供近3萬種蛋白、抗體等核心生命科學(xué)試劑，旨在為生命科學(xué)科研工作者提供專業(yè)、全面、可靠的試劑產(chǎn)品。
試劑 | 耗材 | 定制 | 實驗服務(wù) | 供應(yīng)鏈
免費熱線：027-65279366 /18108604356